Arzerra (ofatumumab) 1000 mg IV GLAXO UK
Article:
G-7
testimony
- Previously untreated chronic lymphocytic leukemia (CLL) Arzerra, together with chlorambucil or bendamustin, is indicated for the treatment of previously untreated CLL patients for whom fludarabine therapy cannot be used.
- Refractory CLL Arzerra is indicated for the treatment of patients with CLL who have failed treatment with fludarabine and Alemtuzumab.
- 820/100, 2340/1000 carats
- azer, arzer, azar
-
Commercial name:Arzerra
-
Сhemical name:ofatumumab
-
Dosage:1000 mg
-
Release form:Ampoule
-
Виробник:Glaxo, великобритания
No reviews yet